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Abstract 
Objective: World Health Organization/ International Network of Rational use of Drugs (WHO/INRUD) 
indicators are widely used to assess medicine use. However, there is limited evidence on their validity in 
Namibia’s primary health care (PHC) to assess the quality of prescribing.  Consequently, our aim was to 
address this. Design, setting, participants and interventions: An analytical cross-sectional survey design 
was used to examine and validate WHO/INRUD indicators in outpatient units of two PHC facilities and 
one hospital from 1st February 2015 to 31st July 2015. The validity of the indicators was determined 
using two-by-two tables against compliance to the Namibian standard treatment guidelines (NSTG). The 
receiver operator characteristics for the WHO/INRUD indicators were plotted to determine their accuracy 
as predictors of compliance to agreed standards. A multivariate logistic model was constructed to 
independently determine the prediction of each indicator. Main outcomes and results: Out of 1243 
prescriptions; compliance to NSTG prescribing in PHCs was sub-optimal (target was >80%). Three of the 
four WHO/INRUD indicators did not meet Namibian or WHO targets: antibiotic prescribing, average 
number of medicines per prescription and generic prescribing. The majority of the indicators had low 
sensitivity and/or specificity. All WHO/INRUD indicators had poor accuracy in predicting rational 
prescribing. The antibiotic prescribing indicator was the only covariate that was a significant independent 
risk factor for compliance to NSTGs. Conclusion: WHO/INRUD indicators showed poor accuracy in 
assessing prescribing practices in PHCs in Namibia. There is need for appropriate models and/or criteria 
to optimize medicine use in PHCs in the future. 
 
Introduction 
 
The World Health Organisation (WHO) estimates the global burden of inappropriate prescribing of 
medicines to be over 50% [1,2]. This is important especially in low and middle income countries (LMICs) 
which have the highest burden of non-communicable and infectious diseases. Moreover, the cost of 
medicines can account for up to 70% of total healthcare costs in LMICs, with a significant proportion out-
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of-pocket [2-4].  Consequently, it is very important to optimize medicine use in these settings. In Namibia, 
over 45% of the adult population currently live with hypertension [5], with cardiovascular diseases (CVD) 
currently accounting for 21% of annual deaths [6].  There are also high rates of infectious disease in 
Namibia leading at times to excessive and over use of antibiotics [7,8]. As a result, there is a need for 
robust systems and indicators to monitor and guide medicine use to enhance appropriate prescribing. 
 
The WHO/ International Network for Rational Use of Drugs (WHO/INRUD) prescribing indicator 
framework was developed as an objective measure for evaluating the appropriateness of medicine use 
[2,9,10]. These indicators are currently seen a proxies for assessing the quality of prescribing as currently 
no international standards have been empirically developed [2]. This is a concern as these indicators are 
widely integrated into health management information systems (HMIS) across countries [2,11,12], and no 
indicator directly measures rational prescribing according to the WHO definition [13]. 
 
Namibia’s public health care is based on a Primary Health Care (PHC) system, funded mainly by the 
government. Currently, the WHO/INRUD indicators are integrated into the Namibian health system at all 
levels of healthcare [13]. The current prescribing targets and rates for the five key indicators are [2,9,14-
17]: 
 Average number of medicines per encounter – WHO Target; Namibia target <2, acceptable – 2.5; 
currently in Namibia: 1.6 – 3.1. However, a high number of medicines per prescription may not 
necessarily mean irrational prescribing as seen in patients with chronic diseases or multimorbidities 
[9,18] 
 % of encounters with an antibiotic prescribed – WHO Target <30%, Namibia target <25%, acceptable 
– 35%; currently in Namibia: 56 – 80%. It is difficult to assess whether these targets represent quality 
prescribing without knowing the presenting infections, which could be viral in origin as typically seen 
with upper respiratory tract infections (URTIs) [19] or the extent of underlying infectious diseases 
such as HIV and TB 
 % of encounters with an injection: WHO Target <20%, Namibia target <10%, acceptable – 15%; safe 
medication use in Namibia 44% - 50% 
 % of medicines prescribed by International non-proprietary name (INN)  - WHO Target 100%, 
Namibia target - 100%, acceptable – 80%; currently in Namibia: 74 - 80%. However, 100% may be 
difficult to achieve with substitution discouraged in a small group of medicines including those for 
epilepsy [20,21], and where there are concerns with the quality of generics [22,23] 
 Compliance to Essential Medicine Lists – WHO Target – 100%. In Namibia – compliance to Standard 
Treatment Guidelines currently at 15.4 – 44.6 % depending on the region; acceptable > 80%  
 
The task to reliably measure the quality of prescribing in PHCs should compare with robust 
methodologies that have been used in other circumstances to assess the  quality of care including the 
Integrated Management of Childhood Illness (IMCI) project, the Adult Primary Care Assessment Tool  
(PACT) and the quality indicators that have been developed for antibiotic prescribing [24-29].  
 
Consequently the aim of this study was to appraise the applicability of current WHO/INRUD prescribing 
indicators in assessing the quality of prescribing in PHC settings in Namibia. Subsequently, use the 
findings if pertinent to suggest the development of different  indicators to guide future prescribing. This 
includes compliance to Namibian Standard Treatment Guidelines (NSTG) [30]. The NSTG, which include 
treatment guidance for patients in both hospital and ambulatory care including community infectious 
diseases, are seen as appropriate for assessing the quality of prescribing based on the WHO definition of 
rational medicine use [12]. This is because STGs in LMICs are typically based on the principles of rational 
use of medicines and adapted from WHO recommendations. We are aware that different treatment 
guidance documents exist in Nambia, which can give conflicting advise [31]. Adopting the NSTG as the 
gold standard helps to address such concerns.  
 
Methods 
 
Study design and setting 
A  cross-sectional design was undertaken to determine the quality of medicine prescribing among public 
health care facilities in Namibia [9]. Prescribing habits of physicians in out-patient departments (OPD), 
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stratified by WHO/ INRUD prescribing indicators , were assessed against compliance with current NSTG 
[30].  
 
The study was conducted in three OPD settings among public health facilities in Khomas region, one of 
the fourteen regions of Namibia that houses Windhoek, the capital city, with a cosmopolitan population 
[32]. The health facilities were selected based on the level of heath care provided, which included a clinic, 
health center and hospital settings, in line with WHO recommendations [9]. These facilities were 
purposively selected because of their large and diverse patient populations and, close proximity to each 
other. In addition, reflective of the situation across Namibia.  
 
Study subjects and procedure 
Patients at the OPD units were stratified by the level of care facility to include two PHC facilities – 
Khomasdal Clinic (KMDC) and Katutura Health Centre (KHC), and one hospital – Intermediate Hospital 
Katutura (IHK). The Khomasdal clinic was purposely selected out of the ten clinics in the Khomas region 
based on its proximity and demographic and service similarity to KHC and IHK. All patients recieving OPD 
care at the selected health facilities were included in the study. The sample size of 1243 for patient 
prescriptions was determined using the Kish Leslie method [33]. This estimation was based on an earlier 
study where compliance to STGs was 26%, giving a p = 0.26 [17]; with β power set at 80%, α = 0.05 with 
a critical value of 1.96 for a two-tailed test.  
 
To evaluate current prescribing practices, we evaluated the most recent prescription in the patients’ 
health passport – that is a prescription written on the day of the study visit that may include more than 
one medicine. The data collection tool (Annex 1) was pre-tested among 10 patients at the OPD at IHK, 
and subsequently refined to improve its robustness. Prescribing data was collected from the patient 
health passports by the research team led by QN and three trained and experienced data collectors using 
the standardized data abstraction tool.  
 
Inclusion and exclusion criteria 
We included all out-patient prescriptions generated from 1st February 2015 to 31st July 2015. We 
excluded prescriptions from inpatient settings and specialist OPDs where the medicine use patterns are 
more complex. We also excluded patients  where the diagnosis was not supported by the signs and 
symproms recorded in the patient’s health passport and those on a follow up visit or reattendance.  
 
Measurement, analysis, validation and criterion development 
The WHO/INRUD prescribing indicators were used as predictors for compliance to the NSTG as the 
principal outcome measure. We determined the level of compliance and prescribing indicators in the OPD 
setting. The sensitivity and specificity of each WHO/INRUD prescribing indicator, e.g. the average number 
of medicines, % precriptions with antibiotics or injections and % of medicines prescribed by INN, was 
assessed as predictors for compliance to the NSTG to determine their validity. The association of the 
other covariates such as the level of health facility, patient demographics, medication prescribed, primary 
diagnosis and/or comorbidities, were also assessed against the WHO/INRUD prescribing indicators.  
 
Quantitative data analysis was undertaken using SPSS Version 23. The WHO/INRUD prescribing 
indicators were determined using descriptive statistics of frequencies. The specificity and sensitivity of the 
prescribing indicators were determined by constructing two-by-two tables for each indicator. A plot of the 
sensitivity against the (1- specificity) was constructed to generate receiver operator characteristic (ROC) 
for each prescribing indicator. The area under the curve (AUC) for the ROC was subsequently 
determined to derive the optimal specificity and sensitivity of the prescribing indicators in determing 
compliance to the NSTG.  
 
The accuracy of the indicator in predicting compliance to the NSTG was classified according to the AUC 
point system: 0.90-1 = excellent, 0.80-.90 = good, 0.70-0.80 = fair; 0.60-0.70 = poor and 0.50-0.59= fail. 
An indicator with an AUC value greater than 0.5 does not rely on chance, and can discriminate between 
prescriptions that are compliant or non-compliant to the NSTG [34]. Consequently, the AUC cut-off was 
set at 0.6 for a valid prescribing indicator. A level of AUC ≥ 0.6 is considered to be of satisfactory 
accuracy in evaluating the sensitivity and specificity of the indicator [34]. 
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Compliance to the NSTG was determined using a correctness score sheet derived from a panel 
incorporating three experts – one clinical pharmacist, one consultant physician and QN from the research 
team. The association between the prescribing indicators and the compliance level was determined using 
bivariate analysis with the Chi-squared test. A multivariate logistic regression analysis was used to 
determine the odds ratios for each prescribing indicator in predicting compliance to NSTG prescribing.  A 
student’s T-test and/or ANOVA were used to determine associations between continuous variables. In 
this study, the level of significance (α) was set at p = 0.05 at a 95% confidence interval.  
 
Ethics 
Permission to conduct the research was granted by the University of Namibia (UNAM) and the Ministry of 
Health and Social Services (MoHSS). Specific patient and prescriber identifiers such as the names and 
ID numbers were not collected but rather a specific numbering was assigned to each study participant for 
purposes of identification.  
 
Results 
We will first discuss compliance to the NSTG and factors involved before discussing the characteristics of 
the prescriptions, in line with the principal objectives. 
 
Level of compliance to the NSTG  
Overall, out of the 1,243 prescriptions (one each from 1243 patients), the majority (73%) complied with 
the NSTG through the appropriate choice of medicine(s) or treatment for the diagnosis indicated. 
Compliance to treatment suggestions in the NSTG was significantly higher at PHC facilities (76.1%) than 
at the hospital (70.5%, p=0.03) (Table 1).  
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Table 1 - Bivariate analysis of factors associated with the compliance to NSTG prescribing 
 
Characteristics Compliance  to NSTG  
Yes (%) No (%) P -value Cramer-V 
Facility level 
Hospital 
PHC 
 
491(70.5) 
416(76.1) 
 
205(29.5) 
131(23.9) 
 
 
0.030* 
 
 
0.062 
Prescriber type  
Medical officer 
Nurse 
 
785(72.4) 
112(77.2) 
 
300(27.6) 
36(22.8) 
 
 
0.198 
 
 
0.036 
Patient gender 
Female 
Male 
 
505(73.1) 
402(72.8) 
 
186(26.9) 
150(27.2) 
 
 
0.919 
 
 
0.003 
Patient age 
Adult (≥ 16 years) 
Child (< 16 years) 
 
701(74.6) 
206(68) 
 
239(25.4) 
97(32) 
 
 
0.025* 
 
 
0.064 
Antimicrobial used  
Yes 
No 
 
565(65.5) 
342(90) 
 
298(34.5) 
38(10) 
 
 
0.000* 
 
 
0.254 
Analgesic used  
Yes 
No 
 
512(72) 
395(74.2) 
 
199(28) 
137(25.8) 
 
 
0.380 
 
 
0.025 
Trained on STG 
Yes 
No 
 
291(72.2) 
616(73.3) 
 
112(27.8) 
224(26.7) 
 
 
0.676 
 
 
0.012 
Resp diagnosis 
Yes 
No 
 
226(70.4) 
676(73.8) 
 
95(29.6) 
240(26.2) 
 
 
0.239 
 
 
0.033 
CVS diagnosis 
Yes 
No 
 
17(81) 
890(72.8) 
 
4(19) 
332(27.2) 
 
 
0.406 
 
 
0.024 
GIT diagnosis 
Yes 
No 
 
25(75.8) 
882(72.9) 
 
8(24.2) 
328(27.1) 
 
 
0.712 
 
 
0.010 
Comorbidity 
Yes 
No 
 
106(75.2) 
801(72.7) 
 
35(24.8) 
301(27.3) 
 
 
0.531 
 
 
0.018 
Antibiotic prescribed 
Yes 
No 
 
483(63.6) 
424(87.6) 
 
276(36.4) 
60(12.4) 
 
 
0.000* 
 
 
0.263 
Generic prescribing 
>80% 
< 80% 
 
346(76) 
559(71.1) 
 
109(24) 
227(28.9) 
 
 
0.062 
 
 
0.053 
Injection prescribing 
Yes 
No 
 
105(78.4) 
802(72.3) 
 
29(21.6) 
307(27.7) 
 
 
0.137 
 
 
0.042 
# medicine prescribed 
< 3 medicines 
> 3 medicines 
 
656(74.9) 
251(68.4) 
 
220(25.1) 
116(31.6) 
 
 
0.019* 
 
 
0.067 
     
Resp = respiratory; CVS = cardiovascular, GIT= gastrointestinal tract;  * = (p < 0.05)-Statistically 
significant- Pearson Chi-square Test 
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Factors associated with compliance to the NSTG by treatment indication  
Compliance with the NSTG was significantly associated (p < 0.05) with the health facility level and type 
(p=0.03), the patients’ age (p=0.025), the prescribing of antimicrobial/antibiotics (p<0.001) and the 
average number of medicines per prescription (p=0.019) (Table 2). There was no significant association 
(p > 0.05) between compliance to the NSTG and prescriber cadre, patient gender, prescribing by INN and 
the presence of analgesics or antihistamines on the prescription (Table 1). There was also no association 
between the level of INN prescribing, the use of injections and prescriber type with compliance to the 
NSTG (Table 1).  
 
Validity of the prescribing indicators against compliance to the NSTG 
The sensitivity rates of the WHO/INRUD indicators ranged from 11.6% to 72.3% (Table 2). The average 
number of medicines per prescription had an acceptable sensitivity (72.3%, p =0.019).  The specificity of 
the WHO/INRUD indicators ranged from 17.9% to 91.4% (Table 2). The injection prescribing indicator had 
an acceptable specificity of 91.43% (p =0.137) (Table 2).   
 
Table 2. Bivariate analysis: validating prescribing indicator against compliance to NSTG  
 
 
 
NSTG Compliant Totals (%) p-value Cramer V 
Yes (%) No (%) 
Antibiotic indicator 
Positive (759) 
Negative(484) 
 
483(53.3)ǂ 
424(46.7) 
 
276(82.1) 
60(17.9)^ 
 
759(61.1) 
484(38.9) 
 
0.000* 
 
 
0.263 
Injection  indicator 
Positive (759) 
Negative(484) 
 
105 (11.6)ǂ 
802(88.4.%) 
 
29(8.6) 
307(91.4)^ 
 
134(10.8) 
1109(89.2) 
 
0.137 
 
 
0.042 
 
Generic indicator 
Positive (759) 
Negative(484) 
 
346(38.2)ǂ 
559(61.8%) 
 
109(32.4) 
227(67.6)^ 
 
455(36.7) 
1109(63.3) 
 
0.60 
 
 
0.053 
 
Average medicines 
< 3 medicines (759) 
>3 medicines (484) 
 
656(72.3)ǂ 
251(27.7) 
 
220(65.5) 
116(34.5)^ 
 
876(70.5) 
367(29.5) 
 
0.019* 
 
 
0.067 
 
      
ǂ = sensitivity; ^ = Specificity; * = significant association – p < 0.005 
 
ROC for the WHO/INRUD indicators against compliance to NSTG 
The ROC test yield failed accuracy for three indicators: Injection prescribing (AUC=0.49; 95%CI: 0.45 – 
0.52, p=0.421), average number of medicines per prescription (AUC=0.46; 95%CI: 0.43 – 0.5, p=0.045), 
generic prescribing (AUC=0.51; 95%CI: 0.48 – 0.55, p=0.46). The antibiotic prescribing indicator had a 
poor accuracy (AUC=0.49; 95%CI: 0.61 – 0.68, p=0.001) (Figure 1). 
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Figure  1 – ROC Curve for medicine use indicators 
 
 
 
Multivariate logistic model for factors associated with compliance to the NSTG 
A logistic regression analysis was conducted to predict compliance to the NSTG for 1240 patients based 
on the health facility level, prescriber cadre category, patient demographics, diagnosis by body system 
and the category of medication prescribed as predictors (Table 3). Three prescription records were 
excluded from the logistic regression analysis due to one or more missing characteristics. A test of the full 
model against a constant only model was statistically significant, indicating that the predictors as a set 
reliably distinguished between compliance and non-compliance to the NSTG prescribing in the PHCs (2 
= 147.2, p<0.001 with df = 34). Nagelkerke’s R2 of 0.163 indicated a relationship between prediction and 
grouping by compliance to NSTGs. Prediction success overall was 73.4% (96.6% for compliance to the 
NSTG and 11.3% for non-compliance). The Wald criterion demonstrated that only prescribing of an 
antibiotic and/or antimicrobial (p<0.001) made a significant contribution to the prediction.   
 
The WHO/INRUD indicators including the average number of medicines per prescription, INN prescribing 
rates and the extent of injection prescribing, were not significant predictors for compliance to the NSTG. 
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In addition, patient’s demographics, prescriber cadre category, diagnosis and the health facility level were 
also not a significant predictor for compliance to the NSTG. One covariate - antibiotic/ antimicrobial 
prescribing (OR=0.2, 95%CI: 0.20 – 0.48) - was identified as an independent risk factor for compliance to 
the NSTG (Table 3). Prescribing of an antibiotic decreases compliance to the NSTG by 80%. 
 
Table 3: Multivariate logistic model for compliance to NSTG prescribing 
 
 
 Covariates  
 
OR(95% CI) 
 
p -value 
Facility level 
Hospital 
PHC 
 
0.7 (0.5, 1.1)  
1.0 
 
 
0.114 
Prescriber cadre 
Medical 
Nursing 
 
0.7 (0.5, 1.1) 
1.0 
 
0.127 
Completed STG training  
Yes 
No 
 
1.1 (0.8, 1.6) 
1.0 
 
0.534 
Patient’s gender 
Female 
Male 
 
1.1(0.8, 1.4) 
1.0 
 
0.677 
Patient’s age (yrs) 
Adult ( ≥16 years) 
Child (< 16 years) 
 
 
0.9(0.6,1.2) 
1.0 
 
 
0.403 
Antibiotic prescribed  
Yes 
No 
 
0.2(0.2,0.48) 
1.0 
 
0.000* 
Injectable prescribed 
Yes 
No 
 
1.5 (0.9,2.4) 
1.0 
 
 
 
0.122 
Number medicines prescribed 
< 3 
> 3 
 
1.1 (0.8, 1.4) 
1.0 
 
0.714 
% generic medicines prescribed 
Yes 
No 
 
1.2 (0.9,1.6) 
1.0 
 
0.309 
Diagnosis by system 
Gastrointestinal 
Musculoskeletal 
Cardiovascular 
Central nervous system 
Obstetrics and gynaecology 
HEENT 
Lower Respiratory Tract 
Genital Urinary Tract 
Fever 
Non specific diagnosis 
 
1.2 (0.7,2.0) 
1.5 (0.9,2.5) 
0.4 (0.1,1.2) 
0.7 (0.2,2.3) 
0.7 (0.2,2.1) 
1.5 (0.9,2.4) 
1.5 (0.5,4.8) 
1.1 (0.6,2.1) 
0.9 (0.3,2.3) 
1.0 
 
0.439 
0.094 
0.110 
0.503 
0.478 
0.117 
0.495 
0.721 
0.821 
 
Comorbidity 
Yes 
No 
 
1.3 (0.8,2.0) 
1.0 
 
0.247 
Treatment prescribed  0.182 
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Antimicrobial  
GIT medication 
Decongestants 
Antihistamines 
Cardiovascular 
Psychiatric  
Emollients 
Non – pharmacotherapy 
Endocrine medicines 
Rehydration salts 
Anti-asthmatic agents 
Analgesics/antinflammatory 
1.0 
0.6 (0.3, 1.0) 
0.3 (0.1,1.1) 
0.6 (0.2,1.7) 
3.5 (0.9,12.7) 
2.4 (0.6,9.9) 
1.2(0.2,6.0) 
1.1(0.5,2.6) 
4.0(0.4,38.5) 
0.6(0.3,1.2) 
0.6(0.1,3.8) 
1.1(0.8,1.7) 
 
 
0.053 
0.069 
0.350 
0.063 
0.222 
0.821 
0.845 
0.226 
0.113 
0.618 
0.501 
Constant 8.1 0.000 
 
 
 
Characteristics of patient prescriptions at OPD units 
The majority of prescriptions were initiated at the OPD of the hospital (56%; p < 0.001), by physicians 
(87.3%; p < 0.001), for females (55.6%; p < 0.008) and adults (≥ 18 years - 73.4%). Table 4 shows the 
bivariate analysis of the WHO/INRUD indicators. The antibiotic prescribing indicator was significantly 
higher among nurse prescribers, children, prescriptions with an antimicrobial, a respiratory diagnosis and 
patients with comorbidities. Antibiotic prescribing was lower with a diagnosis of a cardiovascular or 
gastrointestinal condition. Other areas of interest included INN prescribing associated with the health 
facility (p<0.001), the type of prescriber (p=0.033), co-medication with analgesic (p<0.001) and prescriber 
training on STGs (p<0.001). 
 
Table 4 - Bivariate analysis of factors associated with the WHO/INRUD indicators 
Characteristics Prescription has an antibiotic 
prescribed 
No. medicines per prescription  Prescription has an Injection %  INN prescribing/prescription 
Yes (%) No (%) P -
value 
<3 (%) > 3 (%) P -
value 
Yes (%) No (%) P -
value 
≥80% <80% P -
value 
Facility level 
Hospital 
PHC 
 
409(58.8) 
350(64) 
 
287(41.2) 
197(36) 
 
 
0.069 
 
456(65.5) 
420(76.8) 
 
240(34.5) 
127(23.2) 
 
 
0.000 
 
89(12.8) 
45(8.2) 
 
607(87.2) 
502(91.8) 
 
 
0.01 
 
145(20.9) 
310(56.7) 
 
549(79.1) 
237(43.3) 
 
 
0.000 
Prescriber type  
Medical officer 
Nurse 
 
646(59.5) 
113(71.5) 
 
439(40.5) 
45(28.5) 
 
 
0.004 
 
764(70.4) 
112(70.9) 
 
321(29.6) 
46(29.1) 
 
 
0.903 
 
121(11.2) 
13(8.2) 
 
964(88.8) 
145(91.8) 
 
 
0.268 
 
385(35.5) 
70(44.3) 
 
698(64.5) 
88(55.7) 
 
 
0.033 
Patient gender 
Female 
Male 
 
424(61.4) 
335(60.7) 
 
267(38.6) 
217(39.3) 
 
 
0.815 
 
483(69.9) 
393(71.2) 
 
208(30.1) 
159(28.8) 
 
 
0.618 
 
76(11) 
58(10.5) 
 
615(89) 
494(89.5) 
 
 
0.781 
 
257(37.2) 
198(35.9) 
 
433(62.8) 
353(64.1) 
 
 
0.634 
Patient age 
Adult (≥ 16 years) 
Child (< 16 years) 
 
499(53.1) 
260(85.8) 
 
441(46.9) 
43(14.2) 
 
 
0.000 
 
666(70.9) 
210(69.3) 
 
274(29.1) 
93(30.7) 
 
 
0.609 
 
119(12.7) 
15(5) 
 
821(87.3) 
288(95) 
 
 
0.000 
 
348(37.1) 
107(35.4) 
 
591(62.9) 
195(64.6) 
 
 
0.609 
Antimicrobial used  
Yes 
No 
 
753(87.3) 
6(1.6) 
 
110(12.7) 
374(98.4) 
 
 
0.000 
 
570(66) 
306(80.5) 
 
293(34) 
74(19.5) 
 
 
0.000 
 
86(10) 
48(12.6) 
 
777(90) 
332(87.4) 
 
 
0.163 
 
319(37) 
136(36) 
 
544(63) 
242(64) 
 
 
0.740 
Analgesic used  
Yes 
No 
 
433(60.9) 
326(61.3) 
 
278(39.1) 
206(38.7) 
 
 
0.895 
 
540(75.9) 
336(63.2) 
 
171(24.1) 
196(36.8) 
 
 
0.000 
 
83(11.7) 
51(9.6) 
 
628(88.3) 
481(90.4) 
 
 
0.240 
 
225(31.6) 
230(43.4) 
 
486(68.4) 
300(56.6) 
 
 
0.000 
Trained on STG 
Yes 
No 
 
231(57.3) 
528(62.9) 
 
172(42.7) 
312(37.1) 
 
 
0.061 
 
251(62.3) 
625(74.4) 
 
152(37.7) 
215(25.6) 
 
 
0.000 
 
53(13.2) 
81(9.6) 
 
350(86.8) 
759(90.4) 
 
 
0.062 
 
87(21.6) 
368(43.9) 
 
316(78.4) 
470(56.1) 
 
 
0.000 
Resp diagnosis 
Yes 
No 
 
267(83.2) 
490(53.5) 
 
54(16.8) 
426(46.5) 
 
 
0.000 
 
220(68.5) 
651(71.1) 
 
101(31.5) 
265(28.9) 
 
 
0.392 
 
21(6.5) 
113(12.3) 
 
300(93.5) 
803(87.7) 
 
 
0.004 
 
119(37.1) 
334(36.5) 
 
202(62.9) 
580(63.5) 
 
 
0.866 
CVS diagnosis 
Yes 
No 
 
2 (9.5) 
757(61.9) 
 
19(90.5) 
465(38.1) 
 
 
0.000 
 
16(76.2) 
876(70.5) 
 
5(23.8) 
362(29.6) 
 
 
0.563 
 
1(4.8) 
133(10.9) 
 
20(95.2) 
1089 (89.1) 
 
 
0.370 
 
6(28.6) 
449(36.8) 
 
15(71.4) 
771(63.2) 
 
 
0.438 
GIT diagnosis 
Yes 
No 
 
14(42.4) 
745(61.1) 
 
19(57.6) 
465(38.4) 
 
 
0.026 
 
25(75.8) 
851(70.3) 
 
8(24.2) 
359(29.5) 
 
 
0.500 
 
1(3) 
133(11) 
 
32(97) 
1077(89) 
 
 
0.146 
 
13(40.6) 
442(36.6) 
 
19(59.4) 
767(63.4) 
 
 
0.638 
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Comorbidity 
Yes 
No 
 
99(70.2) 
660(59.9) 
 
42(29.8) 
442(40.1) 
 
 
0.018 
 
70(49.6) 
806(73.1) 
 
71(50.4) 
296(26.9) 
 
 
0.000 
 
10(7.1) 
124(11.3) 
 
131(92.9) 
978(88.7) 
 
 
0.134 
 
48(34) 
407(37) 
 
93(66) 
693(63) 
 
 
0.493 
             
* = (p < 0.05)-Statistically significant- Pearson Chi-squared Test; INN International non-proprietary name 
 
WHO/INRUD prescribing indicators at the primary healthcare facilities 
3,759 medicines were prescribed among the 1,243 prescriptions. The average number of medicines per 
prescription was 3.02 ± 1.14 (IQR = 2 - 4). This was highest at the hospital level (3.15± 1.197) compared 
to the clinic (2.93 ± 1.142) and health center (2.85±1.017) (p=0.004). 63% of medicines were prescribed 
by INN and more than two thirds of the prescriptions included an antibiotic - 69% (; p = 0.059). The 
percentage of prescriptions with ≥ 80% of medicines prescribed by INN was 36.6% (n= 382/1241). 
Injection prescribing was 10.8% (n=134/1243), highest at the hospital 12.8%.  
 
Discussion 
 
The majority of the prescribing indicators according to the WHO/ INRUD criteria were sub-optimal among 
these facilities in Namibia (Table 4). However, 70% of prescriptions in this study had three or less 
medicines prescribed, with an average of 3.12 ±1.14 medicines per prescription. This is similar to other 
African countries [2]. 3759 medicines (63.9%) were prescribed by INN, which is also similar to other 
African countries [2] although lower than Ethiopia at 98.7% [35] and Botswana at 79% [36]. This needs to 
be addressed to avoid patient confusion if different branded generics with different names are dispensed 
on each occasion, with the drive towards lowering generic prices through increased competition [20], and 
patients are unsure whether they are taking the same medicine [37]. There are also concerns with the 
use of injections especially in hospital (Table 1). This will be investigated further to ensure injections are 
not given unnecessarily in the future. 
 
Encouragingly, the majority (73%) of prescriptions were compliant to NSTG recommendations (Table 2). 
This rate is an improvement on a previous study conducted among public facilities in Namibia [17], and  
compares favourably with a recent study among PHCs in Botswana where there were concerns with 
antibiotic prescribing [36]. This high compliance rate in Namibia also compares favourably with 
developing countries where compliance rates have ranged  from 30% to 50% [10,38]. One possible 
reason why our study found a higher compliance rate may be due to the fact that we excluded 
prescriptions where the diagnosis was not supported by the recorded signs and symptoms. Having said 
this, our compliance rate is lower than the compliance level set at 85% by MSH [39] and there are 
concerns that antibiotic prescribing remains suboptimal at most facilities (Table 4). Consequently STG 
compliance was seen as suboptimal, although relatively similar across health facilities.  
 
Overall, all the WHO/INRUD indicators had a poor to fail rating with the AUC of the ROC (Figure 1). In 
addition, all the indicators showed sub-optimal sensitivity and specificity. This raises doubts about the 
appropriateness of the current WHO/ INRUD criteria to assess the quality of prescribing in countries with 
high rates of both infectious and non-infectious diseases such as Namibia and other sub-Sahara African 
countries. This is because our findings suggest a poor performance or accuracy of the WHO/ INRUD 
indicators in evaluating appropriate medicine use in PHCs. A multivariate logistic regression showed that 
only the antibiotic prescribing indicator independently predicted compliance to the NSTG (p < 0.001) 
(Table 3). These findings, together with the recent findings from PHCs in Botswana [36], are a major 
concern as the WHO/INRUD  indicators are still widely used in Namibia and globally to monitor and report 
on medicine use.  
 
Consequently, there is a need to review the use of WHO/INRUD indicators in differing levels of care, 
patient populations, and health sector disease states, and update these building on OMCI, PACT and 
other projects.  This means developing new indicators that more accurately assess the quality of 
prescribing with their validity and reliability robustly tested using agreed methodologies [40, 41]. Possible 
indicators surrounding antibiotic use could include target ratios for broad to narrow-spectrum penicillins, 
cephalosporins and macrolides, as well as target percentage goals for combination penicillins vs. 
amoxycillin and for the fluorquinolones, as these have all been identified as areas of concern to increase 
AMR rates and adverse drug reactions [28,29, 42,43]. There could also be target BP rates for patients 
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with cardiovascular disease given current high prevalence rates in Namibia and concerns with adherence 
[44], as well as HbA1c levels in patients with type 2 diabetes, similar to initiatives in the UK [45, 46]. 
Prescribing targets could also be established for INN prescribing to further improve rates, with greater 
education around INN prescribing starting in medical school to again mirror activities in the UK with its 
high voluntary INN prescribing rate [46]. Potential next steps will include organizing meetings with key 
stakeholder groups to develop and refine potential indicators using robust methodologies to better assess 
the quality of prescribing in the future among PHCs in Namibia. 
 
The main limitation of the study was that it was carried out in only one region of Namibia and with a 
limited number of health facilities. In addition the study was of a cross sectional design carried over a six 
month period, which have their own limitations.  However, we believe our findings are robust based on 
the chosen site and their representational characteristics providing future guidance to improve medicine 
use in Namibia and wider.  
 
Conculsion. 
All the four WHO/INRUD indicators had low validity in predicting the quality of prescribing as outlined in 
the NSTG. In addition, prescribing according to the WHO indicators at health facilities in Namibia were 
sub-optimal. This needs to be addressed. Any developed indicators have to meaningfully assess the 
quality of prescribing in Namibia since only the antibiotic prescribing indicator among the WHO/INRUD 
indicators was an independent covariate for assessing the appropriateness of prescribing based on the 
NSTG. These are projects for the future. 
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